Exclusive: UK biotech raises $33.1M to test CF drug that could work on top of standard of care
Summary
En\xadter\xadprise Ther\xada\xadpeu\xadtics closed a \xa326 mil\xadlion Se\xadries B round to fund a Phase IIa tri\xadal of its cys\xadtic fi\xadbro\xadsis drug, which aims to sig\xadnif\xadi\xadcant\xadly im\xadprove hy\xaddra\xadtion and clear away the mu\xadcus that makes breath\xading dif\xadfi\xadcult for these pa\xadtients.Panakes Part\xadners led the round, along with par\xadtic\xadi\xadpa\xadtion from big-name ex\xadist\xading in\xadvestors like Ver\xadsant Ven\xadtures, No\xadvar\xadtis Ven\xadture Fund and For\xadbion.The UK-based biotech plans to dose the first pa\xadtient with ETD001, its lead drug, in a Phase IIa tri\xadal around East\xader, CEO John Ford told End\xadpoints News, with the first batch of da\xadta set to come out in mid-2025. The tri\xadal, which will be con\xadduct\xaded in the UK and Eu\xadrope, has al\xadready se\xadcured reg\xadu\xadla\xadto\xadry ap\xadproval.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.